Femtech Has Spent Years Being Underfunded Relative to Its Market Size and That Arithmetic Is Changing

The Market That Was Hiding in Plain Sight

Women constitute slightly over half of the global population and account for a disproportionately large share of healthcare utilisation across most age groups. The conditions that affect women exclusively or predominantly, including menstrual disorders, polycystic ovary syndrome, endometriosis, pregnancy and postpartum conditions, and the menopause transition, affect hundreds of millions of women globally and impose substantial costs on individuals, healthcare systems, and employers through their effects on productivity, employment participation, and quality of life. The commercial market for technology products addressing these conditions has been chronically undersupplied relative to the demand that the patient population represents. Venture capital investment in femtech has historically been a fraction of investment in comparable men's health or gender-neutral health technology categories, reflecting a funding community whose gender composition until recently did not include the lived experience of the conditions femtech addresses. The commercial consequence has been a gap between the market opportunity that women's health technology represents and the investment flowing into developing it.

The arithmetic of the femtech market is changing for several reasons that are converging simultaneously. The gender composition of venture capital partnerships is improving modestly, bringing more investors with direct understanding of the conditions femtech addresses to the fund level decision-making that shapes portfolio construction. The menopause market specifically has seen a dramatic increase in commercial attention as the generation of women who drove the wellness industry through their thirties and forties reaches the perimenopause and menopause transition and discovers that the healthcare system's provision for this transition is inadequate. Employer attention to women's health benefits has increased as the commercial cost of menopause-related productivity loss has been quantified by the research that corporate diversity and inclusion programmes have commissioned. And the general maturation of digital health as an investment category has improved the commercial infrastructure, regulatory pathway understanding, and clinical evidence standards that femtech companies can use to build credible investment cases.

Menopause Technology: The Commercial Awakening

The menopause market is the femtech segment whose commercial development has accelerated most dramatically in the past three years. The combination of a large and growing patient population, a healthcare system whose provision has been systematically inadequate, and the advocacy that prominent women in business and media have brought to the menopause conversation has created the commercial conditions for significant investment in menopause technology products and services. The commercial market encompasses hormone monitoring technology, digital therapeutics for symptom management, telehealth platforms connecting women to menopause-specialised clinical care, and the workplace support programmes that employers are developing as part of broader diversity retention initiatives. The clinical need is genuine and large. Estimates suggest that the majority of women experience menopause symptoms that affect their quality of life, and a substantial proportion experience symptoms severe enough to affect their employment. The commercial products addressing this need are developing rapidly, but the evidence base for many of them remains thinner than the marketing suggests, creating the quality variation that characterises a developing commercial market.

Hormone replacement therapy, whose use was dramatically reduced following the Women's Health Initiative study publication in 2002 and which has been gradually rehabilitated as the nuance of that study's findings has been better understood, represents the clinical intervention whose improved uptake is the most commercially significant development in menopause care. The telehealth platforms that provide convenient access to HRT prescribing and monitoring, including Midi Health, Gennev, and Newson Health in the UK, are capturing the demand from women who cannot access timely menopause specialist appointments through conventional healthcare channels. The commercial model of subscription-based menopause telehealth with associated product offerings including prescribed HRT and evidence-based supplements is developing into a recurring revenue business whose customer lifetime value is substantial given the multi-year duration of the perimenopause and menopause transition.

Fertility Technology Beyond IVF

The fertility technology market has historically been defined by IVF clinic technology and the pharmaceutical stimulation protocols that support ovarian stimulation. The commercial development of consumer-facing fertility technology that allows individuals to understand and monitor their fertility before they reach the point of clinical intervention represents a different and growing segment of the femtech market. Cycle tracking applications that use basal body temperature, cervical mucus characteristics, luteinising hormone measurements, and increasingly wearable biosensors to predict fertile windows have developed from basic period tracking into sophisticated fertility awareness tools whose clinical accuracy for natural family planning and fertility optimisation is improving with the machine learning applied to the large datasets that broad user adoption generates. The regulatory environment for fertility tracking technology varies by market and by the claims that products make, with the distinction between fertility awareness as a lifestyle tool and as a medical contraceptive or fertility aid determining the regulatory pathway that commercial products must navigate.

Top 10 Companies in Femtech Globally

1. Natural Cycles: First FDA-cleared contraceptive app using basal body temperature and algorithm-based cycle prediction; its regulatory clearance as a contraceptive device rather than a lifestyle app gives it the clinical credibility that differentiates it from the crowded period tracking market and creates the commercial moat that regulatory approval provides.
2. Midi Health: US menopause telehealth platform connecting women with clinicians specialising in perimenopause and menopause care; its focus on the underserved menopause clinical care gap and its recurring subscription model position it as the commercial leader in the menopause virtual care market whose growth is being driven by demographic demand.
3. Hologic: Medical device company with the broadest women's health portfolio including breast health imaging, surgical products for gynaecological conditions, and diagnostic testing; its commercial scale and clinical relationships make it the incumbent that femtech startups are either partnering with or competing against as they develop clinical-grade products.
4. Ava Women: Wearable fertility tracking bracelet that monitors multiple physiological signals during sleep to predict fertile windows; its clinical validation for fertility awareness positions it above the app-only tracking market and its data asset from millions of cycles is the commercial foundation for AI model improvements that deepen its clinical accuracy advantage.
5. Clue: European menstrual health app with one of the largest cycle tracking datasets globally; its pivot toward clinical research partnerships and its PCOS and endometriosis feature development reflect the commercial strategy of moving from lifestyle tracking toward clinically relevant condition management whose reimbursement potential exceeds consumer app subscription revenue.
6. Elvie: UK femtech hardware company whose Elvie Pump wearable breast pump and Elvie Trainer pelvic floor exerciser have commercialised the intimate health hardware category that most medical device companies treated as too niche to address at commercial scale.
7. Kindbody: Fertility clinic and employer benefits platform combining clinical fertility care with corporate benefit programmes; its employer benefit model that makes fertility benefits a recruitment and retention tool for large employers creates the B2B revenue stream that pure clinic models cannot access.
8. Gennev: Menopause telehealth and digital health platform with clinical care, health coaching, and community support; its acquisition by Unified Women's Healthcare gives it the clinical network access that standalone telehealth companies lack and positions it for the enterprise menopause benefit market.
9. Inne: Salivary progesterone mini-lab for fertility tracking that provides hormone measurement outside clinical settings; its non-invasive hormone measurement approach represents the next generation of consumer fertility monitoring beyond basal body temperature and urine LH testing.
10. Hertility Health: UK women's reproductive health company offering at-home hormone testing, fertility assessment, and clinical referral; its data-driven approach to reproductive health assessment before women reach the point of fertility clinic referral addresses the earliest stage of the fertility care pathway where consumer health technology can have the most commercial and clinical impact.